IMMUNEONCO-B Initiates Phase III Study: First Patient Dosed with Dual-Targeting Therapy IMM0306 for Relapsed/Refractory Follicular Lymphoma

Bulletin Express

Mar 30

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma (R/R FL).

IMM0306 Profile • Mechanism: A bispecific molecule simultaneously targeting CD47 and CD20. • Clinical Milestone: First CD47/CD20 dual-targeting bispecific therapy to reach the clinical stage globally. • Mode of Action: – Blocks the CD47-SIRPα “don’t eat me” signal, enhancing macrophage-mediated phagocytosis. – Strengthens Fc-FcɣRIIa and Fc-FcɣRIIIa interactions to activate macrophages and natural killer cells. – Prefers CD20 over CD47 binding, aiming to eliminate malignant B cells while minimizing toxicity. • Rights: The Group holds global intellectual property and commercial rights to IMM0306.

Regulatory Note In accordance with Rule 18A.05 of the Hong Kong Listing Rules, IMMUNEONCO-B cautions that successful development and commercialization of IMM0306 are not guaranteed.

The announcement was authorized by Chairman and Executive Director Dr. Tian Wenzhi on 30 March 2026 in Shanghai.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1177793692"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177793692\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177793692?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177793692","market":"us","top_or_hot":-1,"title":"IMMUNEONCO-B Initiates Phase III Study: First Patient Dosed with Dual-Targeting Therapy IMM0306 for Relapsed/Refractory Follicular Lymphoma","media":"Bulletin Express","content":"<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma (R/R FL).</p>\n<p>IMM0306 Profile  \n• Mechanism: A bispecific molecule simultaneously targeting CD47 and CD20.  \n• Clinical Milestone: First CD47/CD20 dual-targeting bispecific therapy to reach the clinical stage globally.  \n• Mode of Action:  \n  – Blocks the CD47-SIRPα “don’t eat me” signal, enhancing macrophage-mediated phagocytosis.  \n  – Strengthens Fc-FcɣRIIa and Fc-FcɣRIIIa interactions to activate macrophages and natural killer cells.  \n  – Prefers CD20 over CD47 binding, aiming to eliminate malignant B cells while minimizing toxicity.  \n• Rights: The Group holds global intellectual property and commercial rights to IMM0306.</p>\n<p>Regulatory Note  \nIn accordance with Rule 18A.05 of the Hong Kong Listing Rules, IMMUNEONCO-B cautions that successful development and commercialization of IMM0306 are not guaranteed.</p>\n<p>The announcement was authorized by Chairman and Executive Director Dr. Tian Wenzhi on 30 March 2026 in Shanghai.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMMUNEONCO-B Initiates Phase III Study: First Patient Dosed with Dual-Targeting Therapy IMM0306 for Relapsed/Refractory Follicular Lymphoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMMUNEONCO-B Initiates Phase III Study: First Patient Dosed with Dual-Targeting Therapy IMM0306 for Relapsed/Refractory Follicular Lymphoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-30 22:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma (R/R FL).</p>\n<p>IMM0306 Profile  \n• Mechanism: A bispecific molecule simultaneously targeting CD47 and CD20.  \n• Clinical Milestone: First CD47/CD20 dual-targeting bispecific therapy to reach the clinical stage globally.  \n• Mode of Action:  \n  – Blocks the CD47-SIRPα “don’t eat me” signal, enhancing macrophage-mediated phagocytosis.  \n  – Strengthens Fc-FcɣRIIa and Fc-FcɣRIIIa interactions to activate macrophages and natural killer cells.  \n  – Prefers CD20 over CD47 binding, aiming to eliminate malignant B cells while minimizing toxicity.  \n• Rights: The Group holds global intellectual property and commercial rights to IMM0306.</p>\n<p>Regulatory Note  \nIn accordance with Rule 18A.05 of the Hong Kong Listing Rules, IMMUNEONCO-B cautions that successful development and commercialization of IMM0306 are not guaranteed.</p>\n<p>The announcement was authorized by Chairman and Executive Director Dr. Tian Wenzhi on 30 March 2026 in Shanghai.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1177793692","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177793692","pubTimestamp":1774882102,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"IMMUNEONCO-B启动III期研究：首例接受双重靶向疗法IMM0306治疗复发/难治性滤泡性淋巴瘤的患者","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma (R/R FL).\nIMM0306 Profile  \n• Mechanism: A bispecific molecule simultaneously targeting CD47 and CD20.  \n• Clinical Milestone: First CD47/CD20 dual-targeting bispecific therapy to reach the clinical stage globally.  \n• Mode of Action:  \n  – Blocks the CD47-SIRPα “don’t eat me” signal, enhancing macrophage-mediated phagocytosis.  \n  – Strengthens Fc-FcɣRIIa and Fc-FcɣRIIIa interactions to activate macrophages and natural killer cells.  \n  – Prefers CD20 over CD47 binding, aiming to eliminate malignant B cells while minimizing toxicity.  \n• Rights: The Group holds global intellectual property and commercial rights to IMM0306.\nRegulatory Note  \nIn accordance with Rule 18A.05 of the Hong Kong Listing Rules, IMMUNEONCO-B cautions that successful development and commercialization of IMM0306 are not guaranteed.\nThe announcement was authorized by Chairman and Executive Director Dr. Tian Wenzhi on 30 March 2026 in Shanghai.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}